SEC Form 4 · accession 0001225208-18-015067
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ashley Watson
Officer — SVP Chief Ethics & Com Officer
Period of report
Oct 31, 2018
Accepted (ET)
Nov 1, 2018 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 31, 2018 | M | 23,220 | $59.86 | A | 32,990 | D | |
| Common Stock | Oct 31, 2018 | M | 18,110 | $54.68 | A | 51,100 | D | |
| Common Stock | Oct 31, 2018 | M | 5,706 | $63.97 | A | 56,806 | D | |
| Common StockF1,F2 | Oct 31, 2018 | S | 47,036 | $74.3294 | D | 9,770 | D | |
| Common Stock - 401(k) PlanF3 | holding | — | — | — | 192 | I | By 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $59.86 | Oct 31, 2018 | M | 23,220 | D | May 1, 2016 | Apr 30, 2025 | Common Stock | 23,220 | 0 | D |
| Stock Option (right to buy)F5 | $63.97 | Oct 31, 2018 | M | 5,706 | D | May 5, 2018 | May 4, 2027 | Common Stock | 5,706 | 11,412 | D |
| Stock Option (right to buy)F6 | $54.68 | Oct 31, 2018 | M | 18,110 | D | May 10, 2017 | May 9, 2026 | Common Stock | 18,110 | 9,055 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.1200 to $74.4500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F2Holdings include shares acquired in dividend reinvestment transactions.
- F3Includes shares acquired and dividends earned through October 5, 2018, in the Merck U.S. Savings Plan, a 401(k) plan.
- F4The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.
- F5The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.
- F6The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.